Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics Inc (NQ: CYTH )

0.7412 +0.0305 (+4.29%)
Streaming Delayed Price Updated: 3:51 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclo Therapeutics Inc

< Previous 1 2 3 4 Next >
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million 
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results
From Cyclo Therapeutics
Via Business Wire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements
From Cyclo Therapeutics
Via Business Wire
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the China NPC Association Meeting
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.